BR112017005510A2 - inibidores da histona-desmetilase. - Google Patents

inibidores da histona-desmetilase.

Info

Publication number
BR112017005510A2
BR112017005510A2 BR112017005510A BR112017005510A BR112017005510A2 BR 112017005510 A2 BR112017005510 A2 BR 112017005510A2 BR 112017005510 A BR112017005510 A BR 112017005510A BR 112017005510 A BR112017005510 A BR 112017005510A BR 112017005510 A2 BR112017005510 A2 BR 112017005510A2
Authority
BR
Brazil
Prior art keywords
histone demethylase
demethylase inhibitors
inhibitors
histone
demethylase
Prior art date
Application number
BR112017005510A
Other languages
English (en)
Inventor
Brennan Wallace Michael
K Chen Young
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of BR112017005510A2 publication Critical patent/BR112017005510A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112017005510A 2014-09-17 2015-09-14 inibidores da histona-desmetilase. BR112017005510A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051850P 2014-09-17 2014-09-17
PCT/US2015/049926 WO2016044138A1 (en) 2014-09-17 2015-09-14 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
BR112017005510A2 true BR112017005510A2 (pt) 2018-08-14

Family

ID=55533717

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005510A BR112017005510A2 (pt) 2014-09-17 2015-09-14 inibidores da histona-desmetilase.

Country Status (17)

Country Link
US (3) US9758517B2 (pt)
EP (1) EP3194387B1 (pt)
JP (2) JP6723663B2 (pt)
KR (1) KR20170048601A (pt)
CN (1) CN107001330A (pt)
AU (1) AU2015318111A1 (pt)
BR (1) BR112017005510A2 (pt)
CA (1) CA2961580A1 (pt)
CL (1) CL2017000662A1 (pt)
CO (1) CO2017003445A2 (pt)
EA (1) EA201790604A1 (pt)
EC (1) ECSP17022542A (pt)
ES (1) ES2751464T3 (pt)
IL (1) IL251184A0 (pt)
MX (1) MX2017003463A (pt)
SG (1) SG11201702119PA (pt)
WO (1) WO2016044138A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
CN107001330A (zh) * 2014-09-17 2017-08-01 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AU2018252099B2 (en) * 2017-04-11 2021-08-12 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
CN109709333B (zh) * 2018-08-01 2021-09-24 东南大学 H4k20、h3k9及h3k36三甲基化量检测试剂在食管癌预后评估中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MX2008005666A (es) 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2007328281B2 (en) 2006-12-04 2011-03-31 Novartis Ag Combination of an HDAC inhibitor and an antimetabolite
US20100204231A1 (en) 2007-05-04 2010-08-12 Astrazeneca Ab Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer
JP5114610B1 (ja) * 2009-11-10 2013-01-09 ファイザー・インク N1−ピラゾロスピロケトンアセチル−CoAカルボキシラーゼ阻害薬
ES2534804T3 (es) * 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2013028999A1 (en) 2011-08-24 2013-02-28 The Trustees Of Columbia University In The City Of New York Small molecule inducers of gdnf as potential new therapeutics for neuropsychiatric disorders
CA2885969C (en) * 2012-10-02 2021-04-06 Epitherapeutics Aps Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases
EP2934145B1 (en) 2012-12-19 2017-11-15 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP2968282B1 (en) * 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
CN107001330A (zh) * 2014-09-17 2017-08-01 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂

Also Published As

Publication number Publication date
JP6967632B2 (ja) 2021-11-17
CN107001330A (zh) 2017-08-01
ECSP17022542A (es) 2017-05-31
IL251184A0 (en) 2017-05-29
US20180271843A1 (en) 2018-09-27
WO2016044138A1 (en) 2016-03-24
US20160108032A1 (en) 2016-04-21
ES2751464T3 (es) 2020-03-31
JP2017529347A (ja) 2017-10-05
US20170326116A1 (en) 2017-11-16
CO2017003445A2 (es) 2017-07-11
EP3194387B1 (en) 2019-07-31
US9758517B2 (en) 2017-09-12
EP3194387A4 (en) 2018-03-07
MX2017003463A (es) 2017-07-13
CA2961580A1 (en) 2016-03-24
JP6723663B2 (ja) 2020-07-15
CL2017000662A1 (es) 2018-03-23
JP2020169183A (ja) 2020-10-15
US10231957B2 (en) 2019-03-19
KR20170048601A (ko) 2017-05-08
SG11201702119PA (en) 2017-04-27
AU2015318111A1 (en) 2017-04-13
US10016401B2 (en) 2018-07-10
EA201790604A1 (ru) 2017-09-29
EP3194387A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
BR112017004334A2 (pt) inibidores de desmetilase específica de lisina-1.
DK3160952T3 (da) Histone demethylase inhibitors
BR112017000043A2 (pt) inibidores da desmetilase específica de lisina-1
DK3442972T3 (da) Bromdomænehæmmere
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
IL251103A0 (en) Histone demethylase inhibitors
DK3175063T3 (da) Et forbedret hængsel.
BR112017005511A2 (pt) inibidores da histona-desmetilase.
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3341379T3 (da) EZH2-hæmmere
FR3023988B3 (fr) .
DK3630744T3 (da) Pyrazol-magl-inhibitorer
IL251184A0 (en) Histone demethylase inhibitors
EP3397617A4 (en) INHIBITORS OF HISTONE DEM ETHYLASE
DE102015100749A8 (de) Drehtisch
EP3436445A4 (en) HISTONDEMETHYLASEINHIBITOREN
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
DK3710457T3 (da) Immunproteasomhæmmere
EP3430008A4 (en) INHIBITORS OF HISTONE DEM ETHYLASE
DK3720840T3 (da) Cathepsinhæmmere
EP3445752A4 (en) INHIBITORS OF HISTONE DEM ETHYLASE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 401/14

Ipc: C07D 471/04 (2006.01), A61K 31/437 (2006.01), A61P

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]